Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors

被引：0
|
作者：
Zhang, Songling
Zhu, Xiaoxue
Gao, Lei
Qi, Yaling
Jia, Xiao
Li, Yongguo
Guo, Ye
Ding, Yanhua
机构：
[1] First Hosp Jilin Univ, Gynecol & Obstet Ctr, Dept Gynecol Oncol, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China
[3] First Hosp Jilin Univ, Changchun, Peoples R China
[4] Shanghai Jiatan Pharmatech CO LTD, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14627
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
    Marjorie G. Zauderer
    Evan W. Alley
    Johanna Bendell
    Enrica Capelletto
    Todd M. Bauer
    Sophie Callies
    Anna M. Szpurka
    Suhyun Kang
    Melinda D. Willard
    Volker Wacheck
    Anna M. Varghese
    Investigational New Drugs, 2021, 39 : 1081 - 1088
  • [42] Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
    Zauderer, Marjorie G.
    Alley, Evan W.
    Bendell, Johanna
    Capelletto, Enrica
    Bauer, Todd M.
    Callies, Sophie
    Szpurka, Anna M.
    Kang, Suhyun
    Willard, Melinda D.
    Wacheck, Volker
    Varghese, Anna M.
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1081 - 1088
  • [43] Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
    Hironobu Minami
    Yutaka Fujiwara
    Kei Muro
    Masahiko Sato
    Atsuko Moriya
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 337 - 343
  • [44] Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
    Minami, Hironobu
    Fujiwara, Yutaka
    Muro, Kei
    Sato, Masahiko
    Moriya, Atsuko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 337 - 343
  • [45] A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
    Carlo, Maria I.
    Molina, Ana M.
    Lakhman, Yulia
    Patil, Sujata
    Woo, Kaitlin
    DeLuca, John
    Lee, Chung-Han
    Hsieh, James J.
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Amartin H.
    ONCOLOGIST, 2016, 21 (07): : 787 - 788
  • [46] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [47] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [48] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [49] Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Musib, Luna
    Jones, Cheryl
    De Crespigny, Alex
    Belvin, Marcia
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris
    Shapiro, Geoffrey
    CANCER RESEARCH, 2011, 71
  • [50] Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors
    Lim, Ah Reum
    Kim, Boyeon
    Kim, Jwa Hoon
    Hyun, Myung Han
    Park, Kyong Hwa
    Kim, Yeul Hong
    Lee, Soohyeon
    FRONTIERS IN ONCOLOGY, 2024, 14
12345